尽管Duchenne肌肉萎缩的基因治疗试验结果很有希望, Regenxbio的库存却有所下降。 Regenxbio's stock dropped despite promising gene therapy trial results for Duchenne muscular dystrophy.

Regenxbio的RGNX份额有所下降,尽管RGX-202(Duchenne肌肉萎缩的基因疗法)的中期阶段1/2试验结果良好,但RGX-202(RGX-202)的RGX份额有所下降,这表明,在病人中,运动功能有所改善,心脏健康稳定,微缩营养素表现持续。 Regenxbio's RGNX shares fell despite positive interim Phase 1/2 trial results for RGX-202, a gene therapy for Duchenne muscular dystrophy, showing improved motor function and stable heart health in patients, with sustained microdystrophin expression. 公司预计2026年第二季度初将公布关键数据，并于当年晚些时候与FDA召开BLA前会议，尽管今年迄今上涨52%，股价仍接近52周低点。 The company expects top-line pivotal data in early Q2 2026 and a pre-BLA meeting with the FDA later that year, though the stock remains near 52-week lows despite a 52% year-to-date gain.